HHS Secretary Xavier Becerra (Andrew Harnik/AP Images)
May 31, 2022 12:14 PM EDT
Pharma

Medicare does­n't re­duce its 2022 pre­mi­um hike even as use of Bio­gen's Alzheimer's drug is sharply cur­tailed

Zachary Brennan

Senior Editor

The prospect of the Cen­ters for Medicare & Med­ic­aid Ser­vices (CMS) pay­ing for Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm opened up a mul­ti-bil­lion-dol­lar can of worms …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times